Ivarmacitinib Treat PMR (ESI-PMR)
Efficacy and Safety of Ivarmacitinib for Polymyalgia Rheumatica (ESI-PMR): A 52-Week Open-Label, Randomized, Controlled Clinical Trial
To evaluate the efficacy of the combination of Ivarmacitinib and short-term glucocorticoid induction for remission and rapid discontinuation of glucocorticoids in the treatment of Polymyalgia rheumatica (PMR) , and to compare the differences in the proportion of patients in remission at weeks 24 between the experimental group and control group.
調査の概要
詳細な説明
PMR is a common inflammatory disorder in older adults (aged >50 years), characterized by pain and stiffness in the neck, shoulder girdle, and pelvic girdle. Systemic glucocorticoid administration is the current standard of care, achieving rapid control of inflammation and symptom alleviation. However, standard regimens require prolonged administration (at least 12 months) and are associated with a high rate of relapse during steroid tapering. In this vulnerable population with a high burden of baseline chronic comorbidities (e.g., osteoporosis, diabetes, cardiovascular disease), sustained glucocorticoid use frequently leads to severe adverse effects, such as steroid-induced osteoporosis, peptic ulceration, hyperglycemia, glaucoma, opportunistic infections, and metabolic dysregulation. Consequently, there is an urgent need to explore safer, more effective, and more accessible therapeutic strategies.
Ivarmacitinib, a highly selective JAK1 inhibitor, is approved for rheumatoid arthritis and ankylosing spondylitis, but remains unapproved for PMR. Thus, this protocol represents an investigator-initiated off-label study. Accumulated evidence indicates that JAK1 inhibition holds substantial potential for controlling PMR disease activity and facilitating steroid tapering. To address the current lack of high-level clinical evidence, this study was initiated to assess the 52-week efficacy and safety of ivarmacitinib in patients with PMR.
研究の種類
入学 (推定)
段階
- フェーズ2
- フェーズ 3
連絡先と場所
研究連絡先
- 名前:Weiqian Chen Dr. Chen, Doctor
- 電話番号:860571-87233418
- メール:cwq678@zju.edu.cn
研究連絡先のバックアップ
- 名前:Xinxin Han Dr. Han, Doctor
- 電話番号:860571-87233418
- メール:hxx1992@126.com
研究場所
-
-
Zhejiang
-
Anji、Zhejiang、中国
- Anji People's Hospital
-
コンタクト:
- Chunyan Chen Dr. Chen
- 電話番号:+8618167257305
- メール:375709261@qq.com
-
Haining、Zhejiang、中国
- Haining Kanghua Hospital
-
コンタクト:
- Jiantao Sun Dr. Sun
- 電話番号:+8615967333501
- メール:5598338@qq.com
-
Hangzhou、Zhejiang、中国
- the First Affiliated Hospital, Zhejiang University School of Medicine
-
コンタクト:
- Weiqian Chen Dr. Chen, Doctor
- 電話番号:860571-87233418
- メール:cwq678@zju.edu.cn
-
Huzhou、Zhejiang、中国
- Huzhou First People's Hospital
-
コンタクト:
- Min Ding Dr. Ding
- 電話番号:+8615805827300
- メール:1943902345@qq.com
-
Wenzhou、Zhejiang、中国
- Wenzhou People's Hospital
-
コンタクト:
- Suxian Lin Dr. Lin
- 電話番号:8613957741565
- メール:4268945@qq.com
-
Yiwu、Zhejiang、中国
- the Fourth Affiliated Hospital, Zhejiang University School of Medicine
-
コンタクト:
- Jie Chang Dr. Chang
- 電話番号:8613705790575
- メール:changjie7311@163.com
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- patients who fulfilled the 2012ACR/EULAR criteria for PMR;
- Patients with high activity rheumatic polymyalgia: disease activity score PMR-AS > 10,
- Adults age 50-88, Weight 45-85Kg,
- ESR>40mm/h or CRP >50mg/L(5mg/dl),
- Informed consent.
Exclusion Criteria:
- Patients with known allergies to Ivarmacitinib, prednisone or methylprednisolone,
- Patients with identified giant cell arteritis, systemic lupus erythematosus, rheumatoid arthritis, calcium pyrophosphate deposition (CPPD) arthropathy, and other rheumatic diseases,
- Patients with severe osteoarthritis,
- Subjects with any severe acute, chronic or recurrent infection (e.g. pneumonia or pyelonephritis, recurrent pneumonia, chronic bronchiectasis, tuberculosis, etc.),
- Hepatitis B virus carriers or individuals with chronic active hepatitis B or C, other chronic liver diseases, HIV infection,
- Patients with abnormal liver function (ALT/AST 2 times higher); Moderate to severe renal impairment (glomerular filtration rate <60); hyperlipidemia not improved by lipid-lowering drugs,
- Pregnant or lactating women,
- Patients with a history of malignancy who do not meet the following condition (patients with malignant tumors who have been successfully treated for more than 5 years before screening without any evidence of recurrence),
- Patients with previous visual field disorder or single eye dysfunction, cataract patients,
- Patients with decompensated cardiac insufficiency or severe hypertension or diabetes mellitus, i.e. systolic blood pressure higher than 160mmhg or diastolic blood pressure higher than 100mmhg,
- For patients with abnormal blood routine, lymphocytes <500/mm3 or ANC <1000/mm3 or HGB < 90g/L,
- Patients with active bleeding and peptic ulcer,
- Have used biological agents or added azathioprine, FK506 within 1 month before enrollment,
- Those who have participated in other drug clinical trials within 4 weeks
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Ivarmacitinib
Withdrawal of prednisone within 8 weeks: 15mg daily for 2 weeks, 10mg daily for 4 weeks, 5mg daily for 2 weeks, then discontinue; Take Ivarmacitinib 4mg daily for 24 weeks, then 2mg daily for 28 weeks. |
Withdrawal of prednisone within 8 weeks. Take Ivarmacitinib 4mg daily for 24 weeks, then 2mg daily for 28 weeks. |
|
アクティブコンパレータ:Prednisone
Prednisone 15mg daily was set as the initial treatment of PMR. When improvement was achieved, the dose of Prednisone was reduced to 10mg daily within 4-8 weeks; When remission was achieved, then taper Prednisone gradually by 2.5mg every 10 weeks. Once relapse occurred, the dose increased to the pre-relapse dose. |
The dose of Prednisone was gradually tapered. Once relapse occurred, the dose increased to the pre-relapse dose. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Proportion of patients in remission at weeks 24
時間枠:at weeks 24
|
Proportion of patients in remission at weeks 24 |
at weeks 24
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Proportion of patients in remission at weeks 52
時間枠:at weeks 52
|
Proportion of patients in remission at weeks 52 |
at weeks 52
|
|
PMR-AS score at weeks 24
時間枠:at weeks 24
|
PMR-AS score: CRP (mg/dL)+Patient self-evaluation (0-10 visual scale)+ Physician global assessment (0-10 Visual Scale)+[morning stiffness (min) x0.1]+ EUL (0-3). |
at weeks 24
|
|
CRP at weeks 24
時間枠:at weeks 24
|
CRP at weeks 24 |
at weeks 24
|
|
ESR at weeks 24
時間枠:at weeks 24
|
ESR at weeks 24 |
at weeks 24
|
|
Relapse rate within 52 weeks
時間枠:within 52 weeks
|
Relapse rate within 52 weeks |
within 52 weeks
|
|
Relapse times within 52 weeks
時間枠:within 52 weeks
|
Relapse times within 52 weeks |
within 52 weeks
|
|
Cumulative dose of prednisone within 52 weeks
時間枠:within 52 weeks
|
Cumulative dose of prednisone within 52 weeks |
within 52 weeks
|
|
Cumulative dose of MTX within 52 weeks
時間枠:within 52 weeks
|
Cumulative dose of MTX within 52 weeks |
within 52 weeks
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:Jin Lin, Prof.、First Affiliated Hospital of Zhejiang University
出版物と役立つリンク
一般刊行物
- Camellino D, Dejaco C, Martini F, Cosso R, Bianchi G. Baricitinib in polymyalgia rheumatica and giant cell arteritis: report of six cases. Reumatismo. 2025 Feb 13;77(1). doi: 10.4081/reumatismo.2024.1796. Epub 2024 Oct 28.
- Liu X, Xu L, Zhao C, Liu S, Sun L, Yang L, Xu X, Wu R, Liu X, Zhang J, Xu S, Zhu P, Chen H, Wang X, Lin C, Lin J, Zhan F, Wei H, Huang Q, Liu H, Ma X, Shi G, Lu Y, Geng X, Jiang Z, Zhang N, Tang K, Zhang R, Zhao Y, Xue L, Song S, Shi X, Zhang Z, Liu P, Wang H, Li Z. Efficacy and Safety of Ivarmacitinib, a Selective JAK1 Inhibitor, in Patients With Active Ankylosing Spondylitis: Results From an Adaptive Seamless Phase 2/3 Trial. Arthritis Rheumatol. 2025 Nov;77(11):1512-1523. doi: 10.1002/art.43238. Epub 2025 Aug 5.
- Xu X, Wei H, Liu L, Yang R, Shi Q, Pang D. Ivarmacitinib improves patient-reported outcomes across multiple domains in patients with active ankylosing spondylitis: a post hoc analysis of a phase II/III trial. Front Pharmacol. 2025 Nov 20;16:1710434. doi: 10.3389/fphar.2025.1710434. eCollection 2025.
- Liu J, Jiang Y, Zhang S, Liu S, Su J, Lin C, He X, Wu R, Yang L, Liu H, Duan X, Xu S, Luo H, Liu J, Xie Q, Mi C, Chen L, Zhang N, Gong H, Zhu J, Li Y, Wei H, Qian L, Wang J, Shi X, Jin H, Jiang Z, Xie X, Zhan F, Geng X, Zheng Z, Du Z, Dong G, Sun Y, Zeng X. Ivarmacitinib, a selective Janus kinase 1 inhibitor, in patients with moderate-to-severe active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs: results from a phase III randomised clinical trial. Ann Rheum Dis. 2025 Feb;84(2):188-200. doi: 10.1136/ard-2024-226385. Epub 2025 Jan 3.
- Ma X, Yang F, Wu J, Xu B, Jiang M, Sun Y, Sun C, Yu Y, Xu D, Xiao L, Ren C, Chen C, Ye Z, Liang J, Lin J, Chen W. Efficacy and Safety of Tofacitinib in Patients with Polymyalgia Rheumatica (EAST PMR): An open-label randomized controlled trial. PLoS Med. 2023 Jun 29;20(6):e1004249. doi: 10.1371/journal.pmed.1004249. eCollection 2023 Jun.
- Devauchelle-Pensec V, Carvajal-Alegria G, Dernis E, Richez C, Truchetet ME, Wendling D, Toussirot E, Perdriger A, Gottenberg JE, Felten R, Fautrel BJ, Chiche L, Hilliquin P, Le Henaff C, Dervieux B, Direz G, Chary-Valckenaere I, Cornec D, Guellec D, Marhadour T, Nowak E, Saraux A. Effect of Tocilizumab on Disease Activity in Patients With Active Polymyalgia Rheumatica Receiving Glucocorticoid Therapy: A Randomized Clinical Trial. JAMA. 2022 Sep 20;328(11):1053-1062. doi: 10.1001/jama.2022.15459.
- Buttgereit F, Dejaco C, Matteson EL, Dasgupta B. Polymyalgia Rheumatica and Giant Cell Arteritis: A Systematic Review. JAMA. 2016 Jun 14;315(22):2442-58. doi: 10.1001/jama.2016.5444.
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- IIT20260100C-R1
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Due to the policies of the country, it is not possible to directly share the personal data of the subjects. If the researchers are interested, they can contact the relevant person via email to obtain the summarized data.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。